Hims & Hers Health, Inc. (NYSE:HIMS) Given Consensus Rating of “Hold” by Analysts

Hims & Hers Health, Inc. (NYSE:HIMS) has received a consensus rating of “Hold” from the sixteen analysts that are covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and seven have issued a buy rating on the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $20.71.

A number of brokerages recently weighed in on HIMS. Deutsche Bank Aktiengesellschaft boosted their price target on shares of Hims & Hers Health from $23.00 to $27.00 and gave the stock a “hold” rating in a report on Wednesday, November 6th. Needham & Company LLC initiated coverage on shares of Hims & Hers Health in a research report on Thursday, August 22nd. They set a “buy” rating and a $24.00 target price for the company. Canaccord Genuity Group raised their price target on shares of Hims & Hers Health from $24.00 to $28.00 and gave the stock a “buy” rating in a research note on Tuesday, November 5th. TD Cowen reiterated a “buy” rating and issued a $28.00 price objective on shares of Hims & Hers Health in a research note on Wednesday, November 20th. Finally, Piper Sandler reissued a “neutral” rating and issued a $21.00 target price (up from $18.00) on shares of Hims & Hers Health in a research report on Tuesday, November 5th.

Insider Activity

In other Hims & Hers Health news, insider Soleil Boughton sold 2,345 shares of the company’s stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $14.65, for a total value of $34,354.25. Following the transaction, the insider now directly owns 159,796 shares in the company, valued at $2,341,011.40. This represents a 1.45 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Melissa Baird sold 58,750 shares of Hims & Hers Health stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $21.04, for a total value of $1,236,100.00. Following the sale, the chief operating officer now owns 630,166 shares of the company’s stock, valued at approximately $13,258,692.64. This trade represents a 8.53 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 1,049,183 shares of company stock worth $21,395,632. 17.71% of the stock is owned by company insiders.

Hedge Funds Weigh In On Hims & Hers Health

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Nisa Investment Advisors LLC increased its position in shares of Hims & Hers Health by 679.2% during the 2nd quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company’s stock valued at $37,000 after purchasing an additional 1,603 shares during the last quarter. Quest Partners LLC boosted its stake in Hims & Hers Health by 5,944.1% in the second quarter. Quest Partners LLC now owns 3,566 shares of the company’s stock worth $72,000 after buying an additional 3,507 shares in the last quarter. CWM LLC grew its position in Hims & Hers Health by 21.4% during the third quarter. CWM LLC now owns 5,982 shares of the company’s stock valued at $110,000 after acquiring an additional 1,054 shares during the last quarter. Van ECK Associates Corp purchased a new position in shares of Hims & Hers Health during the second quarter worth approximately $111,000. Finally, Quarry LP lifted its holdings in shares of Hims & Hers Health by 91.0% in the 3rd quarter. Quarry LP now owns 6,113 shares of the company’s stock worth $113,000 after acquiring an additional 2,913 shares during the last quarter. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Price Performance

HIMS opened at $31.39 on Thursday. Hims & Hers Health has a fifty-two week low of $8.09 and a fifty-two week high of $31.40. The firm has a market capitalization of $6.86 billion, a P/E ratio of 71.34 and a beta of 1.06. The company’s 50-day moving average is $20.85 and its 200 day moving average is $19.44.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings data on Monday, November 4th. The company reported $0.32 EPS for the quarter, beating the consensus estimate of $0.06 by $0.26. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The firm had revenue of $401.56 million during the quarter, compared to analyst estimates of $382.20 million. During the same quarter last year, the business posted ($0.04) EPS. The company’s revenue for the quarter was up 77.1% on a year-over-year basis. On average, equities research analysts expect that Hims & Hers Health will post 0.29 earnings per share for the current year.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.